On August 14, Liquidia Technologies Inc rose 5.18% in regular trading, trading at $75.84/share, with turnover of approximately $58.1 million. The stock rebounded following a cumulative decline of over 10% in the prior two trading days.

The rebound comes after the company reported Q2 earnings on August 12. Revenue of $171.7 million grew approximately 18.5x year-over-year, beating the consensus estimate of $168.5 million. Core product YUTREPIA net sales reached approximately $170.4 million, up 31% sequentially, with approximately 5,900 unique patient prescriptions. However, EPS of $0.74 fell slightly short of the FactSet estimate of $0.76. The prior selloff was driven by the EPS miss combined with profit-taking after the stock had more than doubled year-to-date. BofA Securities had previously downgraded the stock to Neutral with a $79 price target, which remains above the current trading level.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)